Thank you to our 3,000+ followers for engaging with Urologic Oncology: Seminars and Original Investigations. Your support helps amplify important work in urologic cancer research, education, and collaboration.
@markballmd@SUO_YUO@UroOnc
🔥The April 2026 issue of 'Urologic Oncology: Seminars and Original Investigations' is now available.
Click here to stay on top of urologic oncology ▶️ https://t.co/rmql0AeTZg
#NowOnline#UroSoMe#MedTwitt
NCI Urologic Oncolgy Branch is still accepting @SUO_YUO fellowship applications - interviews April 13, 14, 20. DM or email [email protected] for more information.
Unraveling smooth muscle-rich #RenalCellCarcinoma: Clinical, oncological, genetic, and pathological insights. #AuthorCommentary
Smooth muscle–rich #RCC is a rare but distinct entity. In the largest cohort to date, smrRCC showed frequent bilateral multifocal disease, unique genetic features, and rare metastatic potential—highlighting the need for genetic testing, surveillance, and nephron-sparing care. #ReadMore on UroToday > https://t.co/f61I4gzWnS @RubenBlachmanMD@MillanBraden@markballmd@theNCI@urogoldjournal
I’ve spent my entire professional career as a cancer surgeon fighting cancer in the OR.
This spring, I’m taking that fight to the mats. 🥋🎗️
Proud to compete in Tap Cancer Out Baltimore on May 9, 2026, representing Culture of Jiu Jitsu Academy.
I'm asking for your help. Please donate below and support the fight:
https://t.co/Yjl2niIGBG
#TapCancerOut #RollToEndCancer #BJJForACause
Unraveling smooth muscle-rich #RenalCellCarcinoma: Clinical, oncological, genetic, and pathological insights. #AuthorCommentary
Smooth muscle–rich #RCC is a rare but distinct entity. In the largest cohort to date, smrRCC showed frequent bilateral multifocal disease, unique genetic features, and rare metastatic potential—highlighting the need for genetic testing, surveillance, and nephron-sparing care. #ReadMore on UroToday > https://t.co/f61I4gzWnS @RubenBlachmanMD@MillanBraden@markballmd@theNCI@urogoldjournal
The editorial team of Urologic Oncology extends its sincere appreciation to our peer reviewers who have completed over 100 manuscript reviews. Their dedication of time, depth of expertise, and thoughtful insight strengthen the journal’s quality and help advance the field.
Kidney cancer management is evolving - how are experts adapting? Dr. Brandon Manley, @Raquib_Hannan, & @DrRanaMcKay join @markballmd for a multidisciplinary discussion on kidney cancer care @_backtableONC#URO263
This episode is supported by: @ferring
https://t.co/w00XyU7es5
Kidney cancer management is evolving. How are experts adapting?
In this installment of BackTable Tumor Board, Dr. Brandon Manley, Dr. Raquibul Hannan, and Dr. Rana McKay join guest host Dr. Mark Ball to share their multidisciplinary perspectives on challenging, real-world kidney cancer cases.
This podcast is supported by: Ferring Pharmaceuticals
Watch the episode here: https://t.co/3VkXRmEhn7
#ONC23 #kidneycancer #oncology #urology
MRI features can distinguish benign from malignant HLRCC-associated renal cysts. Our model could spare >50% of patients with benign cysts from unnecessary surgery.
Huge thanks to my PI @aamalayeri and our amazing team @aryanzg@NIHClinicalCntr !
https://t.co/cRnMnrCdmI
📢Published in the September issue of @UrolOncol
Feasibility and perioperative outcomes of re-operative retroperitoneal robotic partial nephrectomy
Click here to read the article▶️https://t.co/vAqxn0qlj5
#UroSoMe#MedTwitter#kidneycancer
@aamalayeri@NIHClinicalCntr@NIH We miss you already. Thank you for willingness to always pick up the phone to discuss a case, your partnership in research and your friendship.